GlassScriptPhysician profile
Khary Edwards
NPI 1457889024
$5,033.36
in general payments reported to CMS, 2019-2025
43 companies · $1,890 in 2025
The $1,890 reported for 2025 was more than what 75% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.46 · 2022: $414 · 2023: $1,244 · 2024: $1,466 · 2025: $1,890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,588 · Education: $13.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,587.66 |
| Education | $13.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $713.34 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $563.45 | 2022-2025 | Evenity, Prolia, Tepezza |
| Novo Nordisk INC | $441.15 | 2022-2025 | Ozempic, Wegovy |
| Abbott Laboratories | $355.19 | 2022-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $271.04 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $225.31 | 2022-2024 | |
| Radius Health, INC. | $182.05 | 2023-2025 | Tymlos |
| Antares Pharma, INC. | $160.97 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Amneal Pharmaceuticals LLC | $160.82 | 2022-2025 | Unithroid |
| Ascendis Pharma Endocrinology INC | $131.62 | 2024-2025 | Yorvipath |
| Sanofi-Aventis U.S. LLC | $109.37 | 2022-2024 | |
| Tandem Diabetes Care, INC. | $96.01 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $95.41 | 2023-2025 | Synthroid |
| Kyowa Kirin, INC. | $91.15 | 2023-2025 | Crysvita |
| Astrazeneca Pharmaceuticals LP | $89.16 | 2022-2025 | Saphnelo |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $80.63 | 2024-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $79.14 | 2024-2025 | Purified Cortrophin Gel |
| Genentech USA, INC. | $79.14 | 2024-2025 | Actemra |
| E.R. Squibb & Sons, L.L.C. | $78.38 | 2024-2025 | Orencia |
| Insulet Corporation | $74.72 | 2023-2024 | Omnipod |
| Ucb, INC. | $67.26 | 2025 | Bimzelx |
| Amphastar Pharmaceuticals, INC. | $66.88 | 2024-2025 | Baqsimi |
| Horizon Therapeutics Plc | $62.63 | 2023 | Tepezza |
| Sobi, INC | $56.74 | 2024-2025 | |
| Medtronic, INC. | $55.49 | 2024-2025 | Minimed 780g |
| Madrigal Pharmaceuticals | $53.31 | 2025 | Rezdiffra |
| Actelion Pharmaceuticals US, INC. | $53.10 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| Halozyme INC | $52.10 | 2023 | |
| Fresenius Kabi USA, LLC | $51.91 | 2023-2024 | Idacio |
| Janssen Biotech, INC. | $51.09 | 2025 | Tremfya, Simponi Aria |
| Ibsa Pharma INC. | $46.50 | 2023 | Tirosint, Licart |
| Corcept Therapeutics | $43.35 | 2025 | Korlym |
| Neurocrine Biosciences, INC. | $35.11 | 2025 | |
| Cequr Corporation | $35.10 | 2024 | Cequr Simplicity |
| Embecta Corp. | $30.93 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Ultragenyx Pharmaceutical INC. | $27.19 | 2023 | |
| Almatica Pharma LLC | $26.93 | 2025 | Teriparatide |
| Recordati_rare_diseases_inc. | $26.34 | 2025 | Isturisa |
| Aurinia Pharma U.S., INC. | $24.51 | 2024 | Lupkynis |
| Alvogen INC | $24.34 | 2025 | Teriparatide |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.77 | 2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $23.06 | 2024 | Gvoke Hypopen |
| Organon LLC | $17.67 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khary Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.